Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria

Reindl, 2020, International multicenter examination of MOG antibody assays, Neurol Neuroimmunol Neuroinflamm, 7, e674, 10.1212/NXI.0000000000000674 Reindl, 2019, Myelin oligodendrocyte glycoprotein antibodies in neurological disease, Nat Rev Neurol, 15, 89, 10.1038/s41582-018-0112-x Cobo-Calvo, 2018, Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study, Neurology, 90, e1858, 10.1212/WNL.0000000000005560 Jurynczyk, 2017, Clinical presentation and prognosis in MOG-antibody disease: a UK study, Brain, 140, 3128, 10.1093/brain/awx276 Waters, 2020, Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes, JAMA Neurol, 77, 82, 10.1001/jamaneurol.2019.2940 Armangue, 2020, Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study, Lancet Neurol, 19, 234, 10.1016/S1474-4422(19)30488-0 Höftberger, 2020, The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody, Acta Neuropathol, 139, 875, 10.1007/s00401-020-02132-y Takai, 2020, Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study, Brain, 143, 1431, 10.1093/brain/awaa102 de Mol, 2020, The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults, Mult Scler, 26, 806, 10.1177/1352458519845112 O'Connell, 2020, Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK, J Neurol Neurosurg Psychiatry, 91, 1126, 10.1136/jnnp-2020-323158 Thompson, 2018, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, 17, 162, 10.1016/S1474-4422(17)30470-2 Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729 López-Chiriboga, 2018, Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders, JAMA Neurol, 75, 1355, 10.1001/jamaneurol.2018.1814 Jarius, 2018, MOG encephalomyelitis: international recommendations on diagnosis and antibody testing, J Neuroinflammation, 15, 134, 10.1186/s12974-018-1144-2 Marignier, 2021, Myelin-oligodendrocyte glycoprotein antibody-associated disease, Lancet Neurol, 20, 762, 10.1016/S1474-4422(21)00218-0 Cobo-Calvo, 2020, Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease, Ann Neurol, 89, 30, 10.1002/ana.25909 Senanayake, 2019, Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka, J Neurol Neurosurg Psychiatry, 90, 1381 Tea, 2019, Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination, Acta Neuropathol Commun, 7, 145, 10.1186/s40478-019-0786-3 Kaneko, 2017, Clinical, MRI and laboratory features of myelin oligodendrocyte glycoprotein (MOG)-antibody-associated neurologic disease: a study of 259 cases, Mult Scler J, 23, 100 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J Neuroinflammation, 13, 280, 10.1186/s12974-016-0718-0 Chen, 2018, Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: a multicenter study in South China, J Neuroimmunol, 321, 83, 10.1016/j.jneuroim.2018.05.014 Asseyer, 2020, Prodromal headache in MOG-antibody positive optic neuritis, Mult Scler Relat Disord, 40, 10.1016/j.msard.2020.101965 Bennett, 2022, Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment, Lancet Neurol Ramanathan, 2018, Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J Neurol Neurosurg Psychiatry, 89, 127, 10.1136/jnnp-2017-316880 Chen, 2018, Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome, Am J Ophthalmol, 195, 8, 10.1016/j.ajo.2018.07.020 Ramanathan, 2014, Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Neurol Neuroimmunol Neuroinflamm, 1, e40, 10.1212/NXI.0000000000000040 Rempe, 2021, Anti-MOG associated disorder-clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience, Mult Scler Relat Disord, 48, 10.1016/j.msard.2020.102718 Huppke, 2013, Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients, Mult Scler, 19, 941, 10.1177/1352458512466317 Lechner, 2016, Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease, J Neurol Neurosurg Psychiatry, 87, 897, 10.1136/jnnp-2015-311743 Mariano, 2019, Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.12732 Havla, 2021, Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?, J Neuroinflammation, 18, 121, 10.1186/s12974-021-02160-9 Ramanathan, 2019, Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity, Eur J Neurol, 26, 1137, 10.1111/ene.13932 Dubey, 2019, Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody, JAMA Neurol, 76, 301, 10.1001/jamaneurol.2018.4053 Ciron, 2020, Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study, Mult Scler, 26, 936, 10.1177/1352458519849511 Mariano, 2020, Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis, Brain, 144, 198, 10.1093/brain/awaa347 Jitprapaikulsan, 2018, Novel glial targets and recurrent longitudinally extensive transverse myelitis, JAMA Neurol, 75, 892, 10.1001/jamaneurol.2018.0805 Sechi, 2020, Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies, Mult Scler, 20 Asnafi, 2020, The frequency of longitudinally extensive transverse myelitis in MS: a population-based study, Mult Scler Relat Disord, 37, 10.1016/j.msard.2019.101487 Etemadifar, 2021, Conus medullaris involvement in demyelinating disorders of the CNS: a comparative study, Mult Scler Relat Disord, 54, 10.1016/j.msard.2021.103127 Rinaldi, 2020, Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders, Neurol Neuroimmunol Neuroinflamm, 8, e924, 10.1212/NXI.0000000000000924 Fadda, 2021, Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2021.28871 ZhangBao, 2020, Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: a comparative study in Chinese Han patients, Eur J Neurol, 28, 1308, 10.1111/ene.14654 Sechi, 2021, Comparison of MRI lesion evolution in different central nervous system demyelinating disorders, Neurology, 97, e1097, 10.1212/WNL.0000000000012467 Cobo-Calvo, 2016, Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications, Mult Scler, 22, 312, 10.1177/1352458515591071 Chien, 2019, Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity, Mult Scler, 25, 1926, 10.1177/1352458518815596 Camera, 2021, Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder, JAMA Netw Open, 4, 10.1001/jamanetworkopen.2021.37833 Ramanathan, 2016, Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis, Mult Scler, 22, 470, 10.1177/1352458515593406 Jurynczyk, 2017, Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis, Brain, 140, 617, 10.1093/brain/aww350 Banks, 2020, Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS, J Neurol Neurosurg Psychiatry Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement–frequency, presentation and outcome, J Neuroinflammation, 13, 281, 10.1186/s12974-016-0719-z Hyun, 2020, Value of area postrema syndrome in differentiating adults with AQP4 vs MOG antibodies, Front Neurol, 11, 396, 10.3389/fneur.2020.00396 Kunchok, 2020, Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?, Neurology, 94, 85, 10.1212/WNL.0000000000008786 Sinha, 2021, Hemicraniectomy and externalized ventricular drain placement in a pediatric patient with myelin oligodendrocyte glycoprotein-associated tumefactive demyelinating disease, Childs Nerv Syst, 38, 185, 10.1007/s00381-021-05139-2 Hacohen, 2015, Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children, Neurol Neuroimmunol Neuroinflamm, 2, e81, 10.1212/NXI.0000000000000081 Krupp, 2013, International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions, Mult Scler, 19, 1261, 10.1177/1352458513484547 Cobo-Calvo, 2017, MOG antibody-related disorders: common features and uncommon presentations, J Neurol, 264, 1945, 10.1007/s00415-017-8583-z Netravathi, 2021, Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder, J Neurol, 268, 1419, 10.1007/s00415-020-10300-z Baumann, 2015, Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein, J Neurol Neurosurg Psychiatry, 86, 265, 10.1136/jnnp-2014-308346 Hacohen, 2018, ‘Leukodystrophy-like’ phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease, Dev Med Child Neurol, 60, 417, 10.1111/dmcn.13649 Baumann, 2018, MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein, J Neurol, 265, 845, 10.1007/s00415-018-8781-3 Konuskan, 2018, Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders, Mult Scler Relat Disord, 26, 1, 10.1016/j.msard.2018.07.022 Wong, 2018, Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome, Eur J Neurol, 25, 782, 10.1111/ene.13602 Hacohen, 2018, Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease, JAMA Neurol, 75, 478, 10.1001/jamaneurol.2017.4601 Baumann, 2016, Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases, Mult Scler, 22, 1821, 10.1177/1352458516631038 Wegener-Panzer, 2020, Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies, Neurol Neuroimmunol Neuroinflamm, 7, e731, 10.1212/NXI.0000000000000731 Hamid, 2018, Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease, JAMA Neurol, 75, 65, 10.1001/jamaneurol.2017.3196 Ogawa, 2017, MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy, Neurol Neuroimmunol Neuroinflamm, 4, e322, 10.1212/NXI.0000000000000322 Mao, 2019, Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south China: clinical features, treatments, influencing factors, and outcomes, Front Neurol, 10, 868, 10.3389/fneur.2019.00868 Ramanathan, 2019, Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children, Dev Med Child Neurol, 61, 610, 10.1111/dmcn.14032 Martinez-Hernandez, 2020, Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies, Neurology, 94, e2302, 10.1212/WNL.0000000000009239 Lopez-Chiriboga, 2020, Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder, JAMA Neurol, 77, 1575, 10.1001/jamaneurol.2020.3115 Deschamps, 2021, The long-term outcome of MOGAD: an observational national cohort study of 61 patients, Eur J Neurol, 28, 1659, 10.1111/ene.14746 Satukijchai, 2022, Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom, JAMA Netw Open, 5, 10.1001/jamanetworkopen.2021.42780 Akaishi, 2021, Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease, J Neurol, 269, 3136, 10.1007/s00415-021-10914-x Fadda, 2021, Silent new brain MRI lesions in children with MOG-antibody associated disease, Ann Neurol, 89, 408, 10.1002/ana.25957 Akaishi, 2021, Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders, J Neuroimmunol, 351, 10.1016/j.jneuroim.2020.577467 Kim, 2020, Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases, Mult Scler Relat Disord, 40, 10.1016/j.msard.2020.101939 Gastaldi, 2020, Cell-based assays for the detection of MOG antibodies: a comparative study, J Neurol, 267, 3555, 10.1007/s00415-020-10024-0 Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, J Neuroinflammation, 13, 279, 10.1186/s12974-016-0717-1 Mariotto, 2017, Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study, J Neurol, 264, 2420, 10.1007/s00415-017-8635-4 Pedreño, 2019, Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease, Mult Scler Relat Disord, 28, 230, 10.1016/j.msard.2019.01.007 Waters, 2015, MOG cell-based assay detects non-MS patients with inflammatory neurologic disease, Neurol Neuroimmunol Neuroinflamm, 2, e89, 10.1212/NXI.0000000000000089 Akaishi, 2019, Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein, Neurochem Int, 130, 10.1016/j.neuint.2018.10.016 Waters, 2019, A multicenter comparison of MOG-IgG cell-based assays, Neurology, 92, e1250 Cross, 2021, Myelin oligodendrocyte glycoprotein (MOG) antibody positive patients in a multi-ethnic Canadian chort, Front Neurol, 11, 10.3389/fneur.2020.525933 Macrini, 2021, Features of MOG required for recognition by patients with MOG antibody-associated disorders, Brain, 144, 2375, 10.1093/brain/awab105 Sechi, 2021, Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing, JAMA Neurol, 78, 741, 10.1001/jamaneurol.2021.0912 Held, 2021, Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients, Mult Scler J Exp Transl Clin, 7 Mariotto, 2019, Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases, Neurology, 93, e1867, 10.1212/WNL.0000000000008479 Kwon, 2021, Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability, Neurol Neuroimmunol Neuroinflamm, 9 Pace, 2022, Frequency of MOG-IgG in cerebrospinal fluid versus serum, J Neurol Neurosurg Psychiatry, 93, 334, 10.1136/jnnp-2021-326779 Jarius, 2008, Antibody to aquaporin-4 in the long-term course of neuromyelitis optica, Brain, 131, 3072, 10.1093/brain/awn240 Hyun, 2017, Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases, J Neurol Neurosurg Psychiatry, 88, 811, 10.1136/jnnp-2017-315998 Hennes, 2017, Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome, Neurology, 89, 900, 10.1212/WNL.0000000000004312 Cobo-Calvo, 2019, Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults, J Neurol, 266, 806, 10.1007/s00415-018-9160-9 Jarius, 2020, Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients, J Neuroinflammation, 17, 261, 10.1186/s12974-020-01824-2 Kunchok, 2020, Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients, JAMA Neurol, 77, 257, 10.1001/jamaneurol.2019.3656 Fan, 2018, Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis, Mult Scler Relat Disord, 20, 144, 10.1016/j.msard.2018.01.007 Hassan, 2020, Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies, Am J Ophthalmol, 220, 110, 10.1016/j.ajo.2020.07.014 Ducloyer, 2020, MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis, Br J Ophthalmol, 104, 842, 10.1136/bjophthalmol-2019-314845 Stiebel-Kalish, 2017, Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study, PloS One, 12, 10.1371/journal.pone.0170847 Yang, 2020, Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study, Br J Ophthalmol, 106, 262, 10.1136/bjophthalmol-2020-317524 Zhao, 2018, Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients, Br J Ophthalmol, 102, 1372, 10.1136/bjophthalmol-2017-311177 Jarius, 2018, MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature, J Neuroinflammation, 15, 88, 10.1186/s12974-018-1108-6 Cobo-Calvo, 2019, Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study, Neurol Neuroimmunol Neuroinflamm, 7, e649, 10.1212/NXI.0000000000000649 Leite, 2012, Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients, Neurology, 78, 1601, 10.1212/WNL.0b013e31825644ff Kaneko, 2018, CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications, J Neurol Neurosurg Psychiatry, 89, 927, 10.1136/jnnp-2018-317969 Kim, 2020, Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease, Neurol Neuroimmunol Neuroinflamm, 7, e708, 10.1212/NXI.0000000000000708 Mariotto, 2019, Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders, J Neurol Neurosurg Psychiatry, 90, 1293, 10.1136/jnnp-2018-320287 Saxena, 2020, Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases, Sci Rep, 10, 10.1038/s41598-020-69182-w Ciccarelli, 2019, Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders, Lancet Neurol, 18, 185, 10.1016/S1474-4422(18)30460-5 Graves, 2021, Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders, Neurol Neuroimmunol Neuroinflamm, 9 2002, Proposed diagnostic criteria and nosology of acute transverse myelitis, Neurology, 59, 499, 10.1212/WNL.59.4.499